662 related articles for article (PubMed ID: 12011145)
1. Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
Evans DG; Baser ME; McGaughran J; Sharif S; Howard E; Moran A
J Med Genet; 2002 May; 39(5):311-4. PubMed ID: 12011145
[TBL] [Abstract][Full Text] [Related]
2. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1.
McCaughan JA; Holloway SM; Davidson R; Lam WW
J Med Genet; 2007 Jul; 44(7):463-6. PubMed ID: 17327286
[TBL] [Abstract][Full Text] [Related]
3. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years.
Ingham S; Huson SM; Moran A; Wylie J; Leahy M; Evans DG
Eur J Cancer; 2011 Dec; 47(18):2723-8. PubMed ID: 21700447
[TBL] [Abstract][Full Text] [Related]
4. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
5. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
[TBL] [Abstract][Full Text] [Related]
6. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.
Evans DG; O'Hara C; Wilding A; Ingham SL; Howard E; Dawson J; Moran A; Scott-Kitching V; Holt F; Huson SM
Eur J Hum Genet; 2011 Nov; 19(11):1187-91. PubMed ID: 21694737
[TBL] [Abstract][Full Text] [Related]
7. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
[TBL] [Abstract][Full Text] [Related]
8. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.
Hagel C; Zils U; Peiper M; Kluwe L; Gotthard S; Friedrich RE; Zurakowski D; von Deimling A; Mautner VF
J Neurooncol; 2007 Apr; 82(2):187-92. PubMed ID: 17111191
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
[TBL] [Abstract][Full Text] [Related]
10. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
11. Malignant peripheral nerve sheath tumours in inherited disease.
Evans DG; Huson SM; Birch JM
Clin Sarcoma Res; 2012 Oct; 2(1):17. PubMed ID: 23036231
[TBL] [Abstract][Full Text] [Related]
12. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich RE; Hartmann M; Mautner VF
Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
[TBL] [Abstract][Full Text] [Related]
13. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
[TBL] [Abstract][Full Text] [Related]
14. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
[TBL] [Abstract][Full Text] [Related]
15. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.
Park SJ; Sawitzki B; Kluwe L; Mautner VF; Holtkamp N; Kurtz A
BMC Med; 2013 Apr; 11():109. PubMed ID: 23618374
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
17. Malignant peripheral nerve sheath tumors in neurofibromatosis 1.
King AA; Debaun MR; Riccardi VM; Gutmann DH
Am J Med Genet; 2000 Aug; 93(5):388-92. PubMed ID: 10951462
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1.
Hwang IK; Hahn SM; Kim HS; Kim SK; Kim HS; Shin KH; Suh CO; Lyu CJ; Han JW
Cancer Res Treat; 2017 Jul; 49(3):717-726. PubMed ID: 28052660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
